Share Repurchase Program Approved by Becton, Dickinson and Company (NYSE:BDX)

Becton, Dickinson and Company (NYSE:BDX) declared that its board has initiated a share buyback plan on Thursday, November 5th, RTT News reports. The company plans to repurchase 10,000,000 outstanding shares. This buyback authorization allows the medical instruments supplier to buy up to 3.6% of its stock through open market purchases. Stock buyback plans are typically a sign that the company’s board of directors believes its shares are undervalued.

Wall Street Analysts Forecast Growth

BDX has been the subject of a number of recent analyst reports. Weiss Ratings raised shares of Becton, Dickinson and Company from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Monday, September 28th. TD Cowen increased their target price on Becton, Dickinson and Company from $163.00 to $182.00 and gave the company a “hold” rating in a research report on Wednesday, August 5th. Citigroup reaffirmed a “buy” rating on shares of Becton, Dickinson and Company in a research report on Thursday, August 13th. Stifel Nicolaus set a $195.00 price objective on Becton, Dickinson and Company in a report on Friday, August 7th. Finally, Zacks Research raised Becton, Dickinson and Company from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, October 21st. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, eight have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Becton, Dickinson and Company has an average rating of “Moderate Buy” and an average target price of $187.20.

Becton, Dickinson and Company Stock Performance

NYSE BDX traded up $3.86 on Thursday, reaching $213.05. 3,990,398 shares of the company’s stock traded hands, compared to its average volume of 1,721,627. Becton, Dickinson and Company has a fifty-two week low of $127.59 and a fifty-two week high of $214.78. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.51 and a current ratio of 0.87. The firm has a market cap of $58.70 billion, a price-to-earnings ratio of 16.09, a P/E/G ratio of 14.10 and a beta of 0.22. The stock has a 50 day moving average price of $187.69 and a 200-day moving average price of $170.23.

Becton, Dickinson and Company (NYSE:BDX) last posted its earnings results on Thursday, November 5th. The medical instruments supplier reported $4.15 EPS for the quarter, topping the consensus estimate of $4.07 by $0.08. The firm had revenue of $5.27 billion for the quarter, compared to analyst estimates of $5.11 billion. Becton, Dickinson and Company had a return on equity of 14.79% and a net margin of 4.52%. Becton, Dickinson and Company’s revenue for the quarter was up 5.4% compared to the same quarter last year. During the same period last year, the company earned $3.96 earnings per share. Equities research analysts predict that Becton, Dickinson and Company will post 12.67 EPS for the current fiscal year.

Becton, Dickinson and Company Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, December 31st. Stockholders of record on Thursday, December 10th will be given a dividend of $1.06 per share. This is a boost from Becton, Dickinson and Company’s previous quarterly dividend of $1.05. The ex-dividend date is Thursday, December 10th. This represents a $4.24 dividend on an annualized basis and a dividend yield of 2.0%. Becton, Dickinson and Company’s payout ratio is 126.51%.

Insider Activity

In other Becton, Dickinson and Company news, EVP Roland Goette sold 2,438 shares of the company’s stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $180.84, for a total transaction of $440,887.92. Following the completion of the transaction, the executive vice president directly owned 14,856 shares in the company, valued at approximately $2,686,559.04. This represents a 14.10% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Michael Feld sold 165 shares of the stock in a transaction on Wednesday, August 26th. The shares were sold at an average price of $188.49, for a total transaction of $31,100.85. Following the transaction, the executive vice president directly owned 19,720 shares in the company, valued at approximately $3,717,022.80. The trade was a 0.83% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 6,907 shares of company stock worth $1,269,128 over the last three months. 0.40% of the stock is currently owned by corporate insiders.

Key Becton, Dickinson and Company News

Here are the key news stories impacting Becton, Dickinson and Company this week:

• Positive Sentiment: BDX reported adjusted Q4 EPS of $4.15, above analysts’ roughly $4.07 estimate, and revenue of $5.3 billion, up 5.4% year over year and ahead of expectations. For FY2026, free cash flow rose 42.5% to $2.9 billion. BD fiscal 2026 results
• Positive Sentiment: The board raised the quarterly dividend 1% to $1.06 per share, marking its 55th consecutive annual increase, and authorized an additional 10 million share repurchases. These actions may support investor returns and signal confidence in cash generation. Dividend and repurchase announcement
• Positive Sentiment: Evercore ISI raised its price target to $230 from $210, providing a favorable analyst signal. Evercore ISI price-target update
• Negative Sentiment: The main concern is FY2027 guidance: reports characterized the revenue-growth outlook as subdued and the overall outlook as largely in line with expectations. This tempered the positive reaction to the Q4 beat and has put pressure on BDX shares. Coverage of FY2027 guidance

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops, manufactures and sells a broad range of products used by healthcare providers, clinical laboratories, pharmaceutical companies and patients. Its offerings support medication delivery, diagnostics, infection prevention, surgical care and other clinical procedures.

BD’s products include needles, syringes, injection devices, intravenous administration systems, medication-management technologies, specimen-collection products, diagnostic systems and laboratory instruments.